Brii Biosciences Limited Is A Biotechnology Company Listed On The Hong Kong Stock Exchangefocused On Developing Innovative Therapies For Significant Public Health Challengesthe Company Addresses Unmet Medical Needsparticularly In Infectious Diseases And Central Nervous System Disorderswith Operations In Key Biotech Hubs Like Raleigh Durhamthe San Francisco Bay Areabeijingand Shanghaibrii Biosciences Leverages Global Expertise To Advance Its Mission The Company Has A Robust Pipeline Of Therapeutic Candidatesprimarily Targeting Hepatitis B Virushbvinfectiontheir Lead Programs Include The Hbv Functional Cure Programfeaturing Candidates Such As Brii 179A Recombinant Protein Based Immunotherapeuticelebsiranbrii 835Vir 2218 An Hbv Targeting Sirnaand Tobevibartbrii 877 A Broadly Neutralizing Monoclonal Antibodybrii Biosciences Also Explores Treatments For Hivntm Lung Diseaseand Anxiety And Depressive Disordersthe Leadership Teamled By Zhi Hongph D Emphasizes Collaborationas Seen In Their Partnership With Vir Biotechnology
